Analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for ADMA Biologics’ earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.31). ADMA Biologics reported earnings of ($0.55) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 36.4%. The business is scheduled to issue its next quarterly earnings report on Friday, August 10th.
According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.50) to ($1.24). For the next fiscal year, analysts forecast that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.36) to $0.00. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover ADMA Biologics.
A number of equities research analysts have recently issued reports on ADMA shares. LADENBURG THALM/SH SH lowered their price target on shares of ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday. ValuEngine raised shares of ADMA Biologics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 7th. Finally, Maxim Group set a $10.00 price target on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Tuesday, April 24th.
In related news, CEO Adam S. Grossman acquired 52,301 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were bought at an average cost of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the transaction, the chief executive officer now owns 32,527 shares in the company, valued at $155,479.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jerrold B. Grossman acquired 20,921 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $4.78 per share, for a total transaction of $100,002.38. Following the completion of the transaction, the director now owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. Over the last three months, insiders bought 78,222 shares of company stock worth $373,901. Insiders own 16.90% of the company’s stock.
Several hedge funds have recently bought and sold shares of ADMA. Perceptive Advisors LLC increased its position in shares of ADMA Biologics by 429.9% in the fourth quarter. Perceptive Advisors LLC now owns 3,821,102 shares of the biotechnology company’s stock worth $12,266,000 after purchasing an additional 3,100,000 shares during the last quarter. Consonance Capital Management LP increased its position in shares of ADMA Biologics by 164.3% in the fourth quarter. Consonance Capital Management LP now owns 3,367,635 shares of the biotechnology company’s stock worth $10,810,000 after purchasing an additional 2,093,702 shares during the last quarter. Broadfin Capital LLC bought a new position in shares of ADMA Biologics in the fourth quarter worth approximately $3,538,000. 683 Capital Management LLC bought a new position in shares of ADMA Biologics in the fourth quarter worth approximately $3,050,000. Finally, Morgens Waterfall Vintiadis & Co. Inc. bought a new position in shares of ADMA Biologics in the fourth quarter worth approximately $1,605,000. Institutional investors own 37.42% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.